• Search
  • Advanced Search

Review

January 5, 2023


Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, et al.
Clin Mol Hepatol. 2023;29(2):197-205.

Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean...

Review

December 22, 2022


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, et al.
Clin Mol Hepatol. 2023;29(2):206-216.

Liver cancer is the fourth most prevalent and the second most lethal cancer in China. Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma (HCC). Liver...

Review

December 28, 2022


Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, et al.
Clin Mol Hepatol. 2023;29(2):217-229.

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,...

Review

January 30, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, et al.
Clin Mol Hepatol. 2023;29(2):230-241.
Hepatocellular carcinoma (HCC) is the fourth most common cancer and the second leading cause of cancer-related death in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan...

Review

March 20, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clin Mol Hepatol. 2023;29(2):242-251.

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC...

Review

March 10, 2023


Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian...

Review

January 19, 2023


The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Clin Mol Hepatol. 2023;29(2):263-276.

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess...

Review

January 30, 2023


Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, et al.
Clin Mol Hepatol. 2023;29(2):277-292.
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent...

Review

February 1, 2023


Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, et al.
Clin Mol Hepatol. 2023;29(2):293-319.

Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and NRP2 are the receptors of multiple...

Review

February 1, 2023


Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk...

Original Article

November 21, 2022


Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, et al.
Clin Mol Hepatol. 2023;29(2):417-432.

Background/Aims: Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change...

Original Article

January 4, 2023


Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, et al.
Clin Mol Hepatol. 2023;29(2):433-452.

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in...

Original Article

February 1, 2023


Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, et al.
Clin Mol Hepatol. 2023;29(2):453-464.

Background/Aims: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is...

Original Article

February 20, 2023


Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Zhu Liang, et al.
Clin Mol Hepatol. 2023;29(2):465-481.

Background/Aims: Disrupted bile acid regulation and accumulation in the liver can contribute to progressive liver damage and fibrosis. However, the effects of bile acids on the activation of hepatic stellate...

Original Article

January 5, 2023


Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, et al.
Clin Mol Hepatol. 2023;29(2):482-495.

Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in...

Original Article

March 6, 2023


Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, et al.
Clin Mol Hepatol. 2023;29(2):496-509.

Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment...
Current Issue
Volume 29(2); Apr 2023

Most-cited are based on citations from 2021 ~ 2023.

Guideline
1619
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho
Clin Mol Hepatol. 2021;27(3):363-401.   Published online June 22, 2021
View: 12931   Download: 1,088  Citations: 99
Review
1612
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.   Published online March 22, 2021
View: 6068   Download: 388  Citations: 42
Original Article
1574
Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Clin Mol Hepatol. 2021;27(1):110-124.   Published online December 3, 2020
View: 7087   Download: 401  Citations: 42
1564
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon
Clin Mol Hepatol. 2021;27(1):157-174.   Published online November 26, 2020
View: 6459   Download: 321  Citations: 40
Review
1579
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future
Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai
Clin Mol Hepatol. 2021;27(1):70-80.   Published online December 3, 2020
View: 8993   Download: 338  Citations: 38
1566
Current understanding of primary biliary cholangitis
Atsushi Tanaka
Clin Mol Hepatol. 2021;27(1):1-21.   Published online December 3, 2020
View: 9112   Download: 642  Citations: 31
1569
Recent updates on the management of autoimmune hepatitis
Atsumasa Komori
Clin Mol Hepatol. 2021;27(1):58-69.   Published online December 10, 2020
View: 10096   Download: 838  Citations: 30
Original Article
1667
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng
Clin Mol Hepatol. 2022;28(3):483-496.   Published online March 2, 2022
View: 4240   Download: 199  Citations: 29
Guideline
1713
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clin Mol Hepatol. 2022;28(4):583-705.   Published online October 1, 2022
View: 4147   Download: 385  Citations: 28
Review
1580
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.   Published online December 3, 2020
View: 6237   Download: 310  Citations: 28
1568
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Erica Jennison, Christopher D. Byrne
Clin Mol Hepatol. 2021;27(1):22-43.   Published online December 10, 2020
View: 7040   Download: 390  Citations: 28
Original Article
1681
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah
Clin Mol Hepatol. 2022;28(3):565-574.   Published online May 19, 2022
View: 3506   Download: 148  Citations: 27
Review
1644
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163.   Published online November 10, 2021
View: 4525   Download: 299  Citations: 27
1616
Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559.   Published online June 8, 2021
View: 7315   Download: 386  Citations: 26
1621
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.   Published online June 23, 2021
View: 4300   Download: 224  Citations: 25
Original Article
1602
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry
Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim
Clin Mol Hepatol. 2021;27(3):451-462.   Published online February 2, 2021
View: 4867   Download: 277  Citations: 24
Review
1678
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):790-801.   Published online May 11, 2022
View: 3853   Download: 387  Citations: 23
1563
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Gwyneth Soon, Aileen Wee
Clin Mol Hepatol. 2021;27(1):44-57.   Published online November 19, 2020
View: 9984   Download: 319  Citations: 23
1585
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2021;27(2):221-235.   Published online December 3, 2020
View: 5606   Download: 326  Citations: 22
Guideline
KASL clinical practice guidelines for management of chronic hepatitis B
Clin Mol Hepatol. 2022;28(2):276-331.   Published online April 1, 2022
View: 6835   Download: 463  Citations: 20
Review
1624
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho
Clin Mol Hepatol. 2022;28(1):17-30.   Published online July 20, 2021
View: 6856   Download: 539  Citations: 20
1606
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng
Clin Mol Hepatol. 2021;27(4):524-534.   Published online February 23, 2021
View: 11324   Download: 315  Citations: 19
1600
Changes in the epidemiology and management of bacterial infections in cirrhosis
Salvatore Piano, Marta Tonon, Paolo Angeli
Clin Mol Hepatol. 2021;27(3):437-445.   Published online January 28, 2021
View: 4992   Download: 310  Citations: 19
Original Article
1575
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(1):136-143.   Published online December 3, 2020
View: 4257   Download: 158  Citations: 19
1573
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts
Clin Mol Hepatol. 2021;27(1):207-218.   Published online December 3, 2020
View: 4579   Download: 226  Citations: 18
Snapshot
1618
Hepatocellular carcinoma statistics in South Korea
Young Eun Chon, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol. 2021;27(3):512-514.   Published online June 21, 2021
View: 4037   Download: 146  Citations: 17
Review
1664
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424.   Published online February 17, 2022
View: 4754   Download: 480  Citations: 15
Original Article
1567
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clin Mol Hepatol. 2021;27(1):144-156.   Published online December 7, 2020
View: 5624   Download: 246  Citations: 15
1625
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Clin Mol Hepatol. 2021;27(4):589-602.   Published online July 23, 2021
View: 3985   Download: 212  Citations: 14
Review
1578
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada
Clin Mol Hepatol. 2021;27(3):413-424.   Published online December 3, 2020
View: 11259   Download: 429  Citations: 14

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 355
TOTAL : 1299042
Close layer